We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead
Read MoreHide Full Article
Key Takeaways
Immunocore's Kimmtrak sales rose 29% in 2025, supported by broader adoption and reimbursement.
IMCR reported five-year data showing 16% overall survival versus 8% for the control arm.
Immunocore expects phase III TEBE-AM top-line results as early as the second half of 2026.
Immunocore Holdings (IMCR - Free Report) has built its commercial base around Kimmtrak, its only marketed product and a standard treatment for eligible metastatic uveal melanoma patients in most launched markets.
The investor question is whether deeper adoption and upcoming clinical readouts can keep the growth path intact while the company remains highly dependent on one product.
Immunocore Builds on Kimmtrak Momentum
Kimmtrak generated $400 million in sales in 2025, up nearly 29% year over year. That performance reflects continued demand for the drug since its 2022 approval for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.
The product is approved in 39 countries and launched in more than 30. Higher volumes in the United States and Europe, broader reimbursement coverage and continued expansion into additional countries supported adoption.
IMCR Gains Support From Survival Data
Immunocore added an important durability point in April 2026, when five-year follow-up data from the pivotal phase III trial showed a 16% overall survival rate with Kimmtrak versus 8% for the control arm.
Median overall survival was 21.6 months with Kimmtrak compared with 16.9 months for investigator's choice. The longer record strengthens the drug's first-line positioning and may support physician confidence in eligible patients.
Immunocore Targets New Melanoma Settings
The phase III TEBE-AM study is testing Kimmtrak as monotherapy and in combination with standard-of-care checkpoint inhibitors in advanced cutaneous melanoma after prior anti-PD-(L)1 treatment.
Top-line results are expected as early as the second half of 2026. Positive data could move Kimmtrak into a larger setting where no therapy has shown an overall survival benefit after checkpoint inhibitor treatment in a randomized study.
That makes the readout important not only for Immunocore but also for the broader melanoma landscape. Bristol Myers (BMY - Free Report) , through Opdivo, and Merck (MRK - Free Report) , through Keytruda, remain central checkpoint-inhibitor players, giving IMCR's post-checkpoint strategy a clear competitive frame.
Immunocore Holdings PLC Sponsored ADR Price and Consensus
Immunocore is also evaluating Kimmtrak as an adjuvant therapy for uveal melanoma in the registrational phase III ATOM study, led by the European Organisation for Research and Treatment of Cancer.
Moving Kimmtrak into an earlier treatment setting could expand its reach beyond metastatic disease. The timing remains long dated, however, as enrollment in ATOM is expected to be completed in 2028.
Earlier use would also help address one of IMCR's core investment issues. Kimmtrak is the company's revenue base, so broader use within uveal melanoma could support durability even before other pipeline assets mature.
Immunocore's Stock Signals Require Context
The bottom line is that Immunocore has a real commercial foundation, but it is still a concentrated story. Kimmtrak's 2025 sales growth, first-quarter 2026 revenue growth and five-year survival data support the case for continued adoption.
The neutral view and $37 price target reflect that balance. The stock trades above the Zacks sub-industry and sector on a forward 12-month sales basis, even as its growth outlook remains tied to Kimmtrak and clinical execution.
Because a specific Zacks Rank and Style Scores are not assigned here, investors should not read this as a rank-driven call. The current signal is better framed through Kimmtrak's growth, the 2026 cutaneous melanoma catalyst, the longer ATOM timeline and the risk of relying on a single marketed product.
View the Zacks #1 Rank List
Image: Bigstock
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead
Key Takeaways
Immunocore Holdings (IMCR - Free Report) has built its commercial base around Kimmtrak, its only marketed product and a standard treatment for eligible metastatic uveal melanoma patients in most launched markets.
The investor question is whether deeper adoption and upcoming clinical readouts can keep the growth path intact while the company remains highly dependent on one product.
Immunocore Builds on Kimmtrak Momentum
Kimmtrak generated $400 million in sales in 2025, up nearly 29% year over year. That performance reflects continued demand for the drug since its 2022 approval for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.
The product is approved in 39 countries and launched in more than 30. Higher volumes in the United States and Europe, broader reimbursement coverage and continued expansion into additional countries supported adoption.
IMCR Gains Support From Survival Data
Immunocore added an important durability point in April 2026, when five-year follow-up data from the pivotal phase III trial showed a 16% overall survival rate with Kimmtrak versus 8% for the control arm.
Median overall survival was 21.6 months with Kimmtrak compared with 16.9 months for investigator's choice. The longer record strengthens the drug's first-line positioning and may support physician confidence in eligible patients.
Immunocore Targets New Melanoma Settings
The phase III TEBE-AM study is testing Kimmtrak as monotherapy and in combination with standard-of-care checkpoint inhibitors in advanced cutaneous melanoma after prior anti-PD-(L)1 treatment.
Top-line results are expected as early as the second half of 2026. Positive data could move Kimmtrak into a larger setting where no therapy has shown an overall survival benefit after checkpoint inhibitor treatment in a randomized study.
That makes the readout important not only for Immunocore but also for the broader melanoma landscape. Bristol Myers (BMY - Free Report) , through Opdivo, and Merck (MRK - Free Report) , through Keytruda, remain central checkpoint-inhibitor players, giving IMCR's post-checkpoint strategy a clear competitive frame.
Immunocore Holdings PLC Sponsored ADR Price and Consensus
Immunocore Holdings PLC Sponsored ADR price-consensus-chart | Immunocore Holdings PLC Sponsored ADR Quote
IMCR Pursues Earlier Uveal Melanoma Use
Immunocore is also evaluating Kimmtrak as an adjuvant therapy for uveal melanoma in the registrational phase III ATOM study, led by the European Organisation for Research and Treatment of Cancer.
Moving Kimmtrak into an earlier treatment setting could expand its reach beyond metastatic disease. The timing remains long dated, however, as enrollment in ATOM is expected to be completed in 2028.
Earlier use would also help address one of IMCR's core investment issues. Kimmtrak is the company's revenue base, so broader use within uveal melanoma could support durability even before other pipeline assets mature.
Immunocore's Stock Signals Require Context
The bottom line is that Immunocore has a real commercial foundation, but it is still a concentrated story. Kimmtrak's 2025 sales growth, first-quarter 2026 revenue growth and five-year survival data support the case for continued adoption.
The neutral view and $37 price target reflect that balance. The stock trades above the Zacks sub-industry and sector on a forward 12-month sales basis, even as its growth outlook remains tied to Kimmtrak and clinical execution.
Because a specific Zacks Rank and Style Scores are not assigned here, investors should not read this as a rank-driven call. The current signal is better framed through Kimmtrak's growth, the 2026 cutaneous melanoma catalyst, the longer ATOM timeline and the risk of relying on a single marketed product.
IMCR’s Zacks Rank
Immunocore currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.